Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc > New Here

<< Previous

Bullboard Posts

Next >>

Comment by Nitrodouglason Jan 25, 2021 7:07pm

192 Views

Post# 32380485

RE:RE:New Here

Thanks for the heads up Walter. This stock has that diamond in the rough vibe...I'm sure I ain't the only thinking that. Good luck to all, lets hope they can pull a Sernova. Go Canada

<< Previous

Bullboard Posts

Next >>

Debt-free cannabis company set for next stage of growth